Featured Research

from universities, journals, and other organizations

Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows

Date:
September 1, 2011
Source:
International Association for the Study of Lung Cancer
Summary:
Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, according to new research.

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).

Related Articles


Lung adenocarcinoma can display genetic mutations, including anaplastic lymphoma kinase (ALK) rearrangement and epidermal growth factor receptor (EGFR) mutations. Knowing whether the tumor displays either of these oncogenic mutations can be key to effective treatment, as different cancers respond to different agents.

Researchers at Seoul National University genotyped 95 Korean NSCLC patients into three groups: 43 (45%) had EGFR mutations; 15 (16%) showed ALK rearrangement; and 37 (39%) had wild type (WT) NSCLC.

All patients received 500 mg of pemetrexed every 21 days. Treatment was continued until disease progression warranted termination, unacceptable toxicity was found, or until the patient or physician decided to discontinue therapy. Tumor response was evaluated every two cycles, or earlier if there were clinical signs of progression.

Treatment with pemetrexed delayed time to progression (TTP) of the disease by a median 9.2 months in ALK-rearranged patients, compared with 1.4 months for patients with EGFR mutations and 2.9 months for wild type. Overall response rate was 46.7% for ALK-rearranged patients, compared with 4.7% for EGFR mutant and 16.2% for wild type. Disease control rate (DCR), including partial response plus stable disease, was 86.7% in ALK-rearranged patients, compared with 25.6% for EGFR mutant and 56.8% for wild type.

"Our study demonstrates that pemetrexed treatment produced significantly better outcomes in ALK-translocated NSCLC patients than in EGFR mutant or WT patients," researchers wrote. "DCRs, as well as overall response rates, were excellent in ALK-positive patients (86.7% of DCR and 46.7% of ORR). In addition, median TTP was nearly sixfold higher in ALK-positive NSCLC than in ALK-negative patients. ALK positivity alone was an independent predictor for the efficacy of pemetrexed treatment."

Although the study showed that ALK positivity could be a predictive biomarker for pemetrexed efficacy in patients with NSCLC, researchers cautioned that the larger size of the EGFR mutant group may have affected results, and that more studies were needed.


Story Source:

The above story is based on materials provided by International Association for the Study of Lung Cancer. Note: Materials may be edited for content and length.


Cite This Page:

International Association for the Study of Lung Cancer. "Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows." ScienceDaily. ScienceDaily, 1 September 2011. <www.sciencedaily.com/releases/2011/09/110901105406.htm>.
International Association for the Study of Lung Cancer. (2011, September 1). Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows. ScienceDaily. Retrieved January 30, 2015 from www.sciencedaily.com/releases/2011/09/110901105406.htm
International Association for the Study of Lung Cancer. "Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows." ScienceDaily. www.sciencedaily.com/releases/2011/09/110901105406.htm (accessed January 30, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, January 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC: Get Vaccinated for Measles

CDC: Get Vaccinated for Measles

Reuters - US Online Video (Jan. 30, 2015) The CDC is urging people to get vaccinated for measles amid an outbreak that began at Disneyland and has now infected more than 90 people. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Obama To Outline New Plan For Personalized Medicine

Obama To Outline New Plan For Personalized Medicine

Newsy (Jan. 30, 2015) President Obama is expected to speak with drugmakers Friday about his Precision Medicine Initiative first introduced last week. Video provided by Newsy
Powered by NewsLook.com
NFL Concussions Down; Still on Parents' Minds

NFL Concussions Down; Still on Parents' Minds

AP (Jan. 30, 2015) The NFL announced this week that the number of game concussions dropped by a quarter over last season. Still, the dangers of the sport still weigh on players, and parents&apos; minds. (Jan. 30) Video provided by AP
Powered by NewsLook.com
U.S. Wants to Analyze DNA from 1 Million People

U.S. Wants to Analyze DNA from 1 Million People

Reuters - US Online Video (Jan. 30, 2015) The U.S. has proposed analyzing genetic information from more than 1 million American volunteers to learn how genetic variants affect health and disease. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins